Closed Solicitation · DEPARTMENT OF HEALTH AND HUMAN SERVICES
AI Summary
The National Institutes of Health (NIH) plans to issue a Research Opportunity Announcement (ROA) through the National Institute of Child Health and Human Development (NICHD). This opportunity aims to support advancing cures and therapies for endometriosis and reducing diagnostic delays. The ROA will invite applications from eligible organizations to collaborate with NICHD on this initiative. The optional component of this opportunity includes participation in an OTA clinical trial. Interested parties should stay tuned for the official announcement for further details on how to apply.
The purpose of this Notice is to alert the community that NIH plans to publish a Research Opportunity Announcement (ROA) to invite applications from eligible organizations to engage with NICHD to develop, advance, and/or validate new devices, biomarkers, and/or methods or repurpose existing devices for non-invasive diagnosis of endometriosis. The ROA will consist of two stages: 1) An open call for pre-applications from applicants with an interest in submitting an application to Advancing Cures and Therapies and ending ENDOmetriosis diagnostic delays (ACT ENDO); and 2) An invitation-only stage to apply to the Advancing Cures and Therapies and ending ENDOmetriosis diagnostic delays (ACT ENDO) Research Opportunity Announcement to be offered in summer of 2024. No awards will be made in response to the Stage 1 preapplication step, but Stage 1 participation is required to receive an invitation to Stage 2. An award under Stage 2 will be issued as an Other Transactions Agreement (OTA), which is not a grant, contract, or cooperative agreement. OTAs will involve active NIH program management. Please find detailed information at the following link: https://grants.nih.gov/grants/guide/notice-files/NOT-HD-24-016.html
NOTICE OF INFORMATION: NICHD TO ISSUE A RESEARCH OPPORTUNITY ANNOUNCEMENT TO SUPPORT ADVANCING CURES AND THERAPIES AND ENDING ENDOMETRIOSIS DIAGNOSTIC DELAYS - ACT ENDO (OTA CLINICAL TRIAL OPTIONAL) is a federal acquisition solicitation issued by DEPARTMENT OF HEALTH AND HUMAN SERVICES. Review the full description, attachments, and submission requirements on SamSearch before the response deadline.
SamSearch Platform
AI-powered intelligence for the right opportunities, the right leads, and the right time.